Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4/4/25 16:10 | 4/2/25 | VYGR | Health | BioPrd | Biological Products, (No Diag | Ferguson Toby | MA | O | Chief Me | 1 | S | -35 | 3.43 | 0 | -10 | 158 | D | |||||||||||||||
4/4/25 16:08 | 4/2/25 | VYGR | Health | BioPrd | Biological Products, (No Diag | Sandrock Alfred | MA | O | P,CEO | 5 | S.d | -378 | 5.87 | 0 | -64 | 442 | D | |||||||||||||||
2/24/25 16:21 | 2/20/25 | VYGR | Health | BioPrd | Biological Products, (No Diag | Carter Todd Alfred | MA | O | Chief Sc | 5 | S.dm | -83 | 5.49 | 0 | -15 | 124 | D | |||||||||||||||
2/24/25 16:19 | 2/20/25 | VYGR | Health | BioPrd | Biological Products, (No Diag | Swartz Robin | MA | O | COO,CBO | 7 | S.d | -161 | 5.69 | 0 | -28 | 170 | D | |||||||||||||||
2/12/25 16:19 | 2/11/25 | VYGR | Health | BioPrd | Biological Products, (No Diag | Fahey Sandell Jacquelyn | MA | O | GC | 2 | S | -54 | 5.24 | 0 | -10 | 86 | D | |||||||||||||||
2/22/24 16:32 | 2/21/24 | VYGR | Health | BioPrd | Biological Products, (No Diag | Pfreundschuh Peter P. | MA | O | CFO | 1 | S | -28 | 7.46 | 0 | -4 | 176 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |